164 related articles for article (PubMed ID: 19373083)
1. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Stocker R
Curr Opin Lipidol; 2009 Jun; 20(3):227-35. PubMed ID: 19373083
[TBL] [Abstract][Full Text] [Related]
2. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Tanous D; Hime N; Stocker R
Redox Rep; 2008; 13(2):48-59. PubMed ID: 18339247
[TBL] [Abstract][Full Text] [Related]
3. New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Ladopoulou E; Matralis AN; Kourounakis AP
J Med Chem; 2013 Apr; 56(8):3330-8. PubMed ID: 23581491
[TBL] [Abstract][Full Text] [Related]
4. Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice.
Wu BJ; Di Girolamo N; Beck K; Hanratty CG; Choy K; Hou JY; Ward MR; Stocker R
J Pharmacol Exp Ther; 2007 May; 321(2):477-84. PubMed ID: 17293560
[TBL] [Abstract][Full Text] [Related]
5. AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Serebruany VL; Malinin A; Eisert C; Ong S
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):635-41. PubMed ID: 17605642
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory drugs and atherosclerosis.
Moubayed SP; Heinonen TM; Tardif JC
Curr Opin Lipidol; 2007 Dec; 18(6):638-44. PubMed ID: 17993809
[TBL] [Abstract][Full Text] [Related]
7. AGI-1067: a novel vascular protectant for prevention of restenosis.
Franks AM; Gardner SF
Ann Pharmacother; 2006 Jan; 40(1):66-73. PubMed ID: 16303986
[TBL] [Abstract][Full Text] [Related]
8. Succinobucol induces apoptosis in vascular smooth muscle cells.
Midwinter RG; Maghzal GJ; Dennis JM; Wu BJ; Cai H; Kapralov AA; Belikova NA; Tyurina YY; Dong LF; Khachigian L; Neuzil J; Kagan VE; Stocker R
Free Radic Biol Med; 2012 Mar; 52(5):871-9. PubMed ID: 22203369
[TBL] [Abstract][Full Text] [Related]
9. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
Preiss DJ; Sattar N
Int J Clin Pract; 2007 Apr; 61(4):697-701. PubMed ID: 17394445
[TBL] [Abstract][Full Text] [Related]
10. Probucol and succinobucol in atrial fibrillation: pros and cons.
Liu T; Li G
Int J Cardiol; 2010 Oct; 144(2):295-6. PubMed ID: 19278740
[TBL] [Abstract][Full Text] [Related]
11. Vascular protectants for the treatment of atherosclerosis.
Tardif JC; Grégoire J; Lavoie MA; L'Allier PL
Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):385-92. PubMed ID: 15030266
[TBL] [Abstract][Full Text] [Related]
12. Recent and emerging anti-diabetes targets.
Mohler ML; He Y; Wu Z; Hwang DJ; Miller DD
Med Res Rev; 2009 Jan; 29(1):125-95. PubMed ID: 18855890
[TBL] [Abstract][Full Text] [Related]
13. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.
Wu BJ; Kathir K; Witting PK; Beck K; Choy K; Li C; Croft KD; Mori TA; Tanous D; Adams MR; Lau AK; Stocker R
J Exp Med; 2006 Apr; 203(4):1117-27. PubMed ID: 16606673
[TBL] [Abstract][Full Text] [Related]
14. New antidiabetic therapies: innovative strategies for an old problem.
Lehrke M; Marx N
Curr Opin Lipidol; 2012 Dec; 23(6):569-75. PubMed ID: 23069986
[TBL] [Abstract][Full Text] [Related]
15. FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov A; Shanafelt AB
Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
[TBL] [Abstract][Full Text] [Related]
16. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects.
Muldrew KM; Franks AM
Expert Opin Investig Drugs; 2009 Apr; 18(4):531-9. PubMed ID: 19335281
[TBL] [Abstract][Full Text] [Related]
17. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
Zhao L; Jin W; Rader D; Packard C; Feuerstein G
Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
[TBL] [Abstract][Full Text] [Related]
18. The effect of antidiabetic drugs on genes regulating lipid metabolism.
Tomkin GH
Curr Opin Lipidol; 2009 Feb; 20(1):10-6. PubMed ID: 19106706
[TBL] [Abstract][Full Text] [Related]
19. [Novel therapy for atherosclerosis and inflammatory vascular disease].
Inazu A
Nihon Rinsho; 2011 Jan; 69(1):105-9. PubMed ID: 21226269
[TBL] [Abstract][Full Text] [Related]
20. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Wasserman MA; Sundell CL; Kunsch C; Edwards D; Meng CQ; Medford RM
Am J Cardiol; 2003 Feb; 91(3A):34A-40A. PubMed ID: 12645642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
